Centanafadine

Otsuka · EB-1020

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
27 in total
Targets
—
None known yet

What this is

How it works
Norepinephrine, dopamine and serotonin reuptake inhibitor
Tested for
Attention-Deficit Hyperactivity Disorder(ADHD) (2 trials), Attention Deficit Hyperactivity Disorder (ADHD) (2 trials), Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Main trialPhase 3
“The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).”In the company’s words, NCT07759154 on ClinicalTrials.gov
Other names
EB-1020 · Simtriyo

Other drugs for Attention-Deficit Hyperactivity Disorder(ADHD)

All 5 drugs for Attention-Deficit Hyperactivity Disorder(ADHD)

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials27

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 27 May 2027 A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
Phase 3Recruiting Aug 2027 A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Phase 3Recruiting Dec 2027 A Long-term Trial of EB-1020 in Adult Patients With ADHD
Phase 2/3Recruiting Aug 2027 A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Phase 2/3Recruiting Dec 2027 Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Phase 3Completed 11 Apr 2020 A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Phase 3Completed 14 May 2020 A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Phase 3Completed 7 Sep 2021 A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Phase 3Completed 29 Sep 2023 A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
Phase 3Completed 17 Mar 2025 A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
Phase 3Completed 22 Apr 2026 P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Phase 3Completed 24 Apr 2026 A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
Phase 2Completed 20 Feb 2014 Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
Phase 2Completed 4 Jun 2016 Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Phase 2Completed 21 Dec 2019 Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
Phase 2Completed 31 May 2022 Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
Phase 2Completed 19 Aug 2022 A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
Phase 2Completed 16 May 2025 Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
Phase 1Completed 1 Feb 2014 A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
Phase 1Completed 1 Jul 2014 A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Phase 1Terminated Jan 2016 A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects
Phase 1Completed 1 Apr 2021 A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
Phase 1Completed 26 Mar 2023 A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine
Phase 1Completed 26 Apr 2023 A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
Phase 1Completed 18 May 2023 Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
Phase 1Completed 30 Dec 2024 A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
Phase 1Completed 30 Mar 2026 A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Centanafadine

Following is part of Solo: you see every change to Centanafadine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in